Immuno-Oncology Xchange Europe 2019
- What are the recognized and perhaps less recognized predictive biomarkers for immune checkpoint inhibitors or other immuno therapies?
- Are you using biomarker responses in your clinical trials with immuno therapies?
- How are you undertaking to develop novel prognostic or predictive biomarkers?
Chief Medical Officer
After obtaining his Medical Doctor degree in Medical Microbiology at the University of Mainz (Germany) in 1992, Michael Lahn was a fellow at the Department of Hematology and Oncology at the University of Freiburg (Germany). In 1996, he joined the Department of Immunology at National Jewish Research and Medical Center in Denver, Colorado, where he was Instructor. During this time he investigated the role of T cells in early immune responses. In 2000, Michael joined Eli Lilly and Company, where he led drug development teams in early phase drug development for anti-inflammatory and oncology medicines. He was responsible for the development of several novel oncology drugs, including the second generation ASO LY2181308 and the TGF-beta small molecule inhibitor galunisertib. In 2014 Michael joined AstraZeneca’s osimertinib team and contributed to the registration of osimertinib in NSCLC. In Fall of 2015, Michael was named Head of Clinical Development, Europe, at Incyte. He built the global cross-functional drug development team at Incyte’s European hub in Switzerland. In 2019, he joined iOnctura as Chief Medical Officer in Geneva. Michael has authored or co-authored over 100 publications.
- What are your requirements for studying T cell interactions vs. primary tumour targets in order to investigate individual cell function and measure cytotoxicity in a single experiment?
- How important is precise data on thousands of discrete single T-cell:target interactions for you?
- How do you judge the need for a more reliable method for assessment of potency and viability?
- What is your opinion on the importance of recovering individual T-cells of interest, post-assay, alive and why?
Director, Business Development – Europe
Mio Muelthaler has earned his PhD in Molecular Biology at the University of Wuerzburg. He also earned a certificate „Business Science & Management“ in Munich. His career started in R&D at nanotype GmbH, a biotech start-up near Martinsried, where he contributed to the measurement of the smallest binding force ever measured between biomolecules. He also worked at Sigma-Aldrich as Sales Development Manager Life-Science and eCom manager Switzerland, Tecan as a lab-automation and robotics specialist and at Molecular Devices advising drug discovery and bioproduction development customers for e.g. HTP imaging. Today he is responsible for BD in EU at Berkeley Lights.
12:30pm – 1:30pm
- Biomarker – What are we talking about? Predictive, diagnostic, prognostic, ….?
- Is there a general or preferred path how to implement biomarker development in the
- overall drug development process?
- What are the key lessons to be learned from approved immuno-oncology therapeutics?
Chief Eecutive Officer
Randolf Kerschbaumer holds a degree in biotechnology and a PhD from the University of
Natural Resources and Life Sciences, Vienna, Austria. He has more than twenty years of
experience in research and development of biotherapeutics in big pharma organizations and small biotech companies. During his career he held various senior positions, including Head
of Oncology Research at Shire and Head of Antibody Technology at Baxter. He acquired
detailed knowledge of the entire drug development process, from early drug screening to clinical development, in areas of oncology, inflammation and hematologic disorders. Randolf is founder and CEO of OncoOne, an early stage biotech start-up company based in Klosterneuburg near Vienna, Austria.